We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

BMK Benchmark Holdings Plc

-1.00 (-2.7%)
Last Updated: 12:00:13
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Benchmark Holdings Plc LSE:BMK London Ordinary Share GB00BGHPT808 ORD 0.1P
  Price Change % Change Share Price Shares Traded Last Trade
  -1.00 -2.7% 36.00 131,468 12:00:13
Bid Price Offer Price High Price Low Price Open Price
35.00 36.00 36.00 34.90 36.00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 158.28M -32.09M -0.0434 -8.29 266.17M
Last Trade Time Trade Type Trade Size Trade Price Currency
12:00:13 AT 2,099 36.00 GBX

Benchmark (BMK) Latest News (1)

Benchmark (BMK) Discussions and Chat

Benchmark Forums and Chat

Date Time Title Posts
05/12/202320:27Benchmark Holdings Plc505
19/5/202107:35SALMON prices 30 year high and CAT VACCINES are Go-Go566

Add a New Thread

Benchmark (BMK) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type

Benchmark (BMK) Top Chat Posts

Top Posts
Posted at 07/12/2023 08:20 by Benchmark Daily Update
Benchmark Holdings Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker BMK. The last closing price for Benchmark was 37p.
Benchmark currently has 739,352,390 shares in issue. The market capitalisation of Benchmark is £266,166,860.
Benchmark has a price to earnings ratio (PE ratio) of -8.29.
This morning BMK shares opened at 36p
Posted at 05/12/2023 20:27 by newbold120
I suspect it's worth more than that Ed. JNE is the price setter? Interesting he has joined the board
Posted at 01/12/2023 12:42 by edmonda
"FY23 results: consolidation and cash generation" (new report now available)

Link to note:

For the year to 30 September 2023, Benchmark Holdings reported revenue FY23 of £169.6m, +7.5%YoY (currency adjusted +7%YoY) which was 0.7% below our outlook, and adjusted EBITDA of £35.5m, +9%YoY, 5% above our outlook. Net operating cash of £20.0m was almost double FY22 (£10.8m) with a notable improvement in working capital management from £(12.0)m to £(1.0)m underlining efforts to control costs and improve operational efficiency. Net debt was £45.6m, with year-end cash at £36.5m.

The Group reports Genetics operations at normalised levels, early signs of a recovery in shrimp markets positive for Advanced Nutrition, and in the Health segment improved Q1 24 demand visibility with Clean Treat® at improved capacity utilisation. Most significantly, in FY23 the Group exhibited discipline in cost and cash management which establishes a sound platform for growth in FY24.

We revise down our FY24 revenue outlook by -6% and for FY25 by -7% principally due to a 24% reduction in the outlook for Health. For (adj.) EBITDA the adjustments are -4% in FY24 but +3% in FY25, indicative of continued improvements expected in operational efficiency. We maintain our fair value at 63p/share.
Posted at 29/8/2023 08:44 by edmonda
New note and Investor Presentation recording (see full details below)

For the three months to 30th June 2023, Benchmark Holdings reported revenue of £34.3m, -5.5%YoY (currency-adjusted -1%YoY), as 10%YoY growth in Genetics (42% of total) was offset by the impact of reduced demand in global shrimp markets, resulting in a 17%YoY decline in Advanced Nutrition revenues (47% of total). Adjusted EBITDA1 declined 23%YoY (£5.1m), a 14.8% margin (Q3 22: 18.1%); on a currency-adjusted basis -13%YoY. Net operating cash inflow of £1.7m contrasted with £(1.0)m outflow in Q3 22, with net debt of £45.7m (FY22: £59.3m) and healthy cash reserves of £32.9m.

Q3 under-performance in the Advanced Nutrition business area indicates a revision to our full year FY23 outlook and the basis for FY24 estimates; a 7.2% reduction in our FY23 (adj.) EBITDA outlook and -7.2% for FY24. We maintain our fair value at 63p/share, backed by sound cashflow management, confidence in Genetics salmon eggs demand and production capacity and prospects for Benchmark’s Ectosan®Vet and Clean Treat® treatments.

Link to research report:
Posted at 24/5/2023 14:39 by murdo mcsponge
In the light of the Q figs released, what on earth justifies a 5% drop in the Stock's price, and the sale of over 7 million shares? I presume the sales are by AIM holders which would go to prove that UK investors just don't understand The Company and its products and services, and their position in what might be called a "Sunrise" Industry. No wonder The Board decided to focus on The Oslo Exchange. The Norwegians really understand Aquaculture, and have made fortunes out of it.
Posted at 24/5/2023 13:05 by edmonda
H1 23 results: a robust base for expansion (new research report from Equity Development)

For the six months to 31/3/2023, Benchmark Holdings reported revenue of £98.9m, +24.8%YoY (currency-adjusted +19%YoY), and (adj.) EBITDA of £22.1m, +39.2%YoY (currency-adjusted +36%YoY), a 22.3% margin. Adjusted for the fair value of biological assets, the increase in (adj.) EBITDA was 47%YoY. Underlying the strength of H1 performance, net operating cash inflow of £9.5m was almost 5x H1 22 levels, with net debt reduced to £44.5m (FY22: £47.5m) and cash including facilities at £53.9m. As CEO Trond Williksen commented, after three years of consolidation the Group is now in a position to enter a phase of organic expansion, with the potential for bolt on acquisitions in core areas - under strict criteria. Benchmark also reports that, having completed consultations, it plans to maintain a dual listing on Euronext Growth Olso and LSE AIM, and continue to review listing on the Oslo Børs.

At this stage we maintain our FY23 outlook. We expect revenue drivers in the core Advanced Nutrition business area to normalise and gather pace towards the year end. Revenue in Genetics continues to be driven by firm demand for salmon eggs; we note the pace of diversification in Iceland and Chile. Likewise, demand in Health should accelerate in line with sea lice seasonal demand. Our fair value for Benchmark remains 63p/share.

Link to full report:
Posted at 26/4/2023 14:55 by belfast_child
Maybe we will see BMK move into profit next quarter? Fingers crossed.
Posted at 22/3/2023 09:50 by edwardt
dnb out with a buy rating on bmk. you get the feeling this is being held back big time given the delisting position...
Posted at 03/3/2023 07:59 by edmonda
"Q1 results: consistent growth continues"

Full detailed report & audio summary:

Summary: For the three months to 31 December 2022, Benchmark Holdings reported revenue +36.2%YoY at £54.5m, and (adj.) EBITDA +47.7%YoY (excluding fair value adjustment for biological assets, +61%YoY), to £11.0m reflecting the combination of strong top line growth, capacity utilisation and cost control. As a result, (adj.) EBITDA profitability continued to improve, from an average of 19.7% through FY22, to 20.1%. The operating loss was £0.12m (Q122: £1.46m loss), on an adjusted basis, a £0.85m profit. The Q1 cash position was £42.8m and net debt (excluding leases) reduced from £47.5m at December 2022 to £37.9m1. Cash at 24 February 2023 was £37.5m.

The strength of Q1 23 performance, and in particular the contribution from the Health business area, gives substance to Benchmark’s stated confidence in the outlook for FY23. We have raised our FY23 (adj.) EBITDA outlook by 11% to £36.5m, and for FY24 by 9% to £43.0m, equating to a FY24 EV/EBITDA of 8.0x.

Our fair value for Benchmark remains 63p/share.
Posted at 25/10/2022 07:04 by edmonda
That was a positive update on a strong Q4 and BMK now sees FY22 adj EBITDA beating market expectations.

Equity Development's fair value for now stays at 63p/share, vs 37p in the market, as you can read in new research note here (free access):
Posted at 23/3/2022 20:51 by hedgehog 100
It's interesting to note BMK's strong cash position:
"Cash of £50.6m and Liquidity (cash and available facility) of £61.6m as at 21 February 2022"

Considering the buy-&-build strategy employed by BMK, then OTAQ, which has BMK founder Malcolm Pye as a director, could be a potential BMK takeover target.

In fact, at its current share price of just 20.5p OTAQ looks a sitting duck for a BMK takeover attempt, and looks a prefect fit.

Thought I think that it would have to pay at least double or treble OTAQ's current share price to succeed.

"Malcolm Pye
Non Executive Director
Malcolm founded, and from 1999 to 2019 was Chief Executive of, Benchmark Holdings plc ("Benchmark"), the world's leading aquaculture health, nutrition and genetics business. Malcolm has over 35 years' experience in international agribusiness through his various roles at Hillsdown Holdings (then HMTF Group), and through building Benchmark from the initial start-up into a major international aquaculture technology business serving the global salmon, shrimp, tilapia and farmed fish industries. Malcolm focused Benchmark's activities on animal health, breeding and genetics, advanced nutrition and knowledge/technology delivery and led the flotation of Benchmark in 2013, maintaining a lead role in investor engagement."
Benchmark share price data is direct from the London Stock Exchange

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 |